Vera Therapeutics, Inc. (NASDAQ:VERA) Short Interest Update

Vera Therapeutics, Inc. (NASDAQ:VERAGet Rating) saw a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 941,300 shares, an increase of 28.2% from the June 15th total of 734,500 shares. Approximately 7.9% of the shares of the stock are sold short. Based on an average trading volume of 92,000 shares, the short-interest ratio is presently 10.2 days.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, insider Joanne Curley sold 5,887 shares of Vera Therapeutics stock in a transaction on Friday, June 17th. The shares were sold at an average price of $15.04, for a total value of $88,540.48. Following the sale, the insider now directly owns 23,994 shares in the company, valued at approximately $360,869.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Vera Therapeutics news, insider Joanne Curley sold 5,887 shares of Vera Therapeutics stock in a transaction on Friday, June 17th. The shares were sold at an average price of $15.04, for a total value of $88,540.48. Following the sale, the insider now directly owns 23,994 shares in the company, valued at approximately $360,869.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Sean Grant purchased 5,000 shares of Vera Therapeutics stock in a transaction on Wednesday, June 15th. The stock was bought at an average price of $13.60 per share, for a total transaction of $68,000.00. Following the completion of the acquisition, the chief financial officer now owns 2,816 shares in the company, valued at approximately $38,297.60. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 26,202 shares of company stock worth $395,039. Insiders own 43.10% of the company’s stock.

Hedge Funds Weigh In On Vera Therapeutics

A number of large investors have recently made changes to their positions in the company. Amalgamated Bank purchased a new stake in Vera Therapeutics in the 1st quarter valued at about $34,000. UBS Group AG purchased a new stake in Vera Therapeutics in the 1st quarter valued at about $47,000. New York State Common Retirement Fund boosted its position in Vera Therapeutics by 445.8% in the 4th quarter. New York State Common Retirement Fund now owns 6,549 shares of the company’s stock valued at $175,000 after buying an additional 5,349 shares during the period. American International Group Inc. boosted its position in Vera Therapeutics by 29.2% in the 1st quarter. American International Group Inc. now owns 6,794 shares of the company’s stock valued at $160,000 after buying an additional 1,535 shares during the period. Finally, MetLife Investment Management LLC purchased a new stake in Vera Therapeutics in the 1st quarter valued at about $209,000. 78.57% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Price Performance

VERA stock opened at $16.19 on Wednesday. Vera Therapeutics has a 12 month low of $12.28 and a 12 month high of $37.11. The company has a current ratio of 7.90, a quick ratio of 7.90 and a debt-to-equity ratio of 0.04. The company has a 50-day moving average price of $14.57 and a 200 day moving average price of $19.05. The stock has a market cap of $438.26 million, a PE ratio of -7.39 and a beta of 0.27.

Vera Therapeutics (NASDAQ:VERAGet Rating) last released its quarterly earnings results on Monday, May 16th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.04). Equities research analysts anticipate that Vera Therapeutics will post -3.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on VERA shares. HC Wainwright started coverage on shares of Vera Therapeutics in a report on Monday, May 2nd. They issued a “buy” rating and a $35.00 target price on the stock. Wedbush started coverage on shares of Vera Therapeutics in a report on Monday, April 18th. They issued an “outperform” rating and a $32.00 target price on the stock. JPMorgan Chase & Co. started coverage on shares of Vera Therapeutics in a report on Tuesday, July 12th. They issued an “overweight” rating and a $35.00 target price on the stock. Finally, Lifesci Capital restated an “outperform” rating on shares of Vera Therapeutics in a report on Monday, March 28th.

About Vera Therapeutics

(Get Rating)

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy.

Further Reading

Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.